866-997-4948(US-Canada Toll Free)

Zelapar Analysis and Estimates from 2002 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 31 Pages


GlobalDatas pharmaceuticals report, Zelapar Analysis and Estimates from 2002 to 2020 provides Zelapar sales estimates for US, and UK. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Zelapar including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Zelapar including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Zelapar in the US & UK
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Parkinsons Disease 5
2.2 Symptoms of Parkinsons Disease 5
2.3 Diagnosis of Parkinsons Disease 6
2.4 Parkinsons Disease Treatment Strategies 6
2.5 Parkinsons Disease Market 7
2.6 Epidemiology 7
2.7 Parkinsons Disease by Age and Gender 7
2.8 Etiology 8
2.9 GlobalData Report Guidance 9

3 Parkinsons Disease: Market Characterization 10
3.1 Parkinsons Disease Market 10
3.2 Parkinsons Disease Market Forecasts and CAGR 10
3.3 Factors Affecting Parkinsons Disease Market 11
3.3.1 High Prevalence: Parkinsons Disease is the Second Most Frequent Neurodegenerative Disorder 11
3.3.2 Increase in Old Age Population 11
3.3.3 Patent Expiry of Prominent Drugs 11

4 Stages of Parkinsons Disease and Comparison of Treatments 12
4.1 The Hoehn and Yahr Scale 12
4.2 Modified Hoehn and Yahr Scale 12
4.3 The UPDRS 13

5 Staging of Parkinsons Disease 16
5.1 Distribution of Parkinsons Disease Patients by Age Groups 16
5.2 Distribution of Patients by Stages 16

6 Zelapar 17
6.1 Introduction 17
6.2 Mechanism of Action 17
6.3 Clinical Studies 17
6.4 Approval History of Zelapar 18
6.5 Factors Affecting Sales of Zelapar 18
6.5.1 Low Efficacy 18
6.5.2 Not approved in Japan 19
6.5.3 Patients Switching from Conventional Selegiline to Zelapar 19
6.6 Drug Evaluation 19
6.6.1 Drug Risk Benefit Score 19
6.6.2 Intensity of Competition 20
6.7 Sales Estimates 21
6.7.1 Target Patient Pool for Parkinson s disease 21
6.7.2 Dosing 22
6.7.3 Market Penetration 22
6.7.4 Annual Cost of Therapy 23
6.7.5 Sales Estimates of Zelapar 24

7 Parkinson Disease Market: Appendix 27
7.1 Market Definitions 27
7.2 List of Abberiviations 27
7.3 Research Methodology 27
7.3.1 Coverage 27
7.3.2 Secondary Research 28
7.3.3 Forecasting 28
7.3.4 Number of Patients Approved to take the Drug 28
7.3.5 Net Penetration of Drug 28
7.3.6 Net Annual Dosing 29
7.3.7 Annual Cost of Therapy 29
7.3.8 Primary Research 29
7.3.9 Expert Panels 30
7.4 Drug Sales Estimates Model 30
7.5 Contact Us 30
7.6 Disclaimer 31
7.7 Sources 31

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 5
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 12
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 12
Table 4: Four Items, Part 1 of UPDRS 13
Table 5: Thirteen Items, Part 2 of UPDRS 13
Table 6: Fourteen Items, Part 3 of UPDRS 14
Table 7: Fourteen Items, Part 3 of UPDRS 14
Table 8: Distribution of Parkinsons Patients According to Hoehn and Yahr Classification 16
Table 9: Change in Mean total daily OFF time 17
Table 10: Change in Mean Total Daily OFF Time 17
Table 11: Adverse Events Reported by Patients Treated with Zelapar 18
Table 12: Approval History of Zelapar 18
Table 13: Reduction in OFF Time Reported by Marketed Drugs 18
Table 14: Reduction in OFF Time Reported by Pipeline Drugs 19
Table 15: Zelapar vs. Conventional Selegiline 19
Table 16: Drug Risk Benefit Score 19
Table 17: Efficacy in Terms of Reduction in OFF Time 20
Table 18: Major Adverse Events Reported by Zelapar 20
Table 19: Efficacy comparison of Zelapar 21
Table 20: Efficacy comparison of Zelapar 23
Table 21: : Annual Cost of Zelapar for Parkinsons Disease, 2010 23
Table 22: Zelapar, Parkinsons Disease, Global, Sales Estimates ($m), 20022020 24
Table 23: Zelapar, Parkinsons Disease, The US, Sales Estimates ($m), 20062020 25
Table 24: Zelapar, Parkinsons Disease, UK, Sales Estimates ($m), 20022020 26

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 6
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 8
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 10
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 11
Figure 5: Points Distribution of UPDRS 15
Figure 6: Distribution of Parkinsons Disease Patients by Hoehn & Yahr Classification 16
Figure 7: Drug Model Diagram of Zelapar (Adjunct therapy in the US) 21
Figure 8: Drug Model Diagram of Zelapar ( Adjunct and Monotherapy in UK) 22
Figure 9: Zelapar , Parkinsons Disease, Global, Sales Estimates ($m), 20022020 24
Figure 10: Zelapar, Parkinsons Disease, The US, Sales Estimates ($m), 20062020 25
Figure 11: Zelapar, Parkinsons Disease, The UK, Sales Estimates ($m), 20022020 26
Figure 12: Drug Model Diagram 29
Figure 13: Patients Approved for the Drug 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *